nach oben

Erschienen in:

01.06.2019 | Case report

Hydroxychloroquine

Cutaneous drug eruption: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

A 58-year-old man developed cutaneous drug eruption during treatment with hydroxychloroquine for rheumatoid arthritis. Four days following the hydroxychloroquine therapy [route and dosage not stated], he developed a widespread pruritic, macular, erythematous and symmetrically-distributed rash. His hydroxychloroquine and findings of skin biopsy were compatible with drug eruption. Hydroxychloroquine was discontinued, following which his rash resolved. He had received hydroxychloroquine 20 years previously for several years without any complications, and had discontinued hydroxychloroquine as his wife wanted to get pregnant. …

Cox C, et al. Hydroxychloroquine: A previously well tolerated drug causing an adverse cutaneous reaction when reintroduced 20 years later. Australasian Journal of Dermatology 60 (Suppl. 1): 30, May 2019. Available from: URL: http://doi.org/10.1111/ajd.13027 [abstract] - Australia

Titel: Hydroxychloroquine
Cutaneous drug eruption: case report
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63737-3

Springer Medizin

Hydroxychloroquine

Cutaneous drug eruption: case report

Excerpt

Weitere Artikel der Ausgabe 1/2019

Niacin overdose

Darunavir

Bevacizumab/docetaxel/ramucirumab

Idarucizumab

Pembrolizumab

Nivolumab

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Niacin overdose

Darunavir

Bevacizumab/docetaxel/ramucirumab

Idarucizumab

Pembrolizumab

Nivolumab